Saturday 17 October 2026
Export BCAB’s income statement to Excel — free account
BioAtla, Inc.
BCAB Healthcare Biotechnology
BioAtla, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 81.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4,233.3%, EPS grew 101.7% and free cash flow grew 97.0%, each against the same quarter a year earlier.
1.36
0.06
+4.62%
Follow BCAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.39 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (16.41) | |
P/B ratio |
— | — | — | 0.00 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.89 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (0.67) | |
EV/FCF |
— | — | — | (0.67) | |
Quick Ratio |
0.46 | 0.32 | 0.09 | 0.17 | |
Current Ratio |
0.54 | 0.37 | 0.15 | 0.20 | |
Net Debt/EBITDA |
0.61 | 0.63 | 0.21 | (6.80) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.97 | |
Operating CF/Net income |
0.63 | 0.81 | 0.83 | (0.93) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 51.42% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 45.09% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 9.52% | |
Graham Net Nets |
— | — | — | (6.03) | |
Graham Number |
— | — | — | 111.78 | |
Earnings Yield |
— | — | — | (614.73%) | |
Free Cash Flow Yield |
— | — | — | (342.99%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 3.91 | |
Operating CF per Share |
(8.41) | (6.73) | (3.51) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(8.41) | (6.73) | (3.51) | (0.25) | |
Cash per Share |
7.08 | 6.05 | 1.31 | 0.93 | |
Shareholders Equity per Share |
(26.59) | (30.76) | (24.85) | (21.82) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(26.59) | (30.76) | (24.85) | (21.82) | |
Free Cash Flow |
(9.88) | (7.91) | (5.27) | (0.42) | |
Working Capital |
(8.31) | (13.91) | (17.60) | (16.76) | |
Net Current Asset Value |
(37.47) | (42.00) | (42.78) | (41.48) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
17.51 | 15.03 | 17.29 | 17.62 | |
Average Assets |
39.07 | 33.13 | 23.43 | 18.32 | |
Average Common Equity |
(4.13) | (10.96) | (18.38) | (26.49) |
Columns are period end dates